Pathfinder Cell Therapy, Inc.
PFND
$0.00
$0.000.00%
OTC PK
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -67.50% |
| Gross Profit | -- | -- | -- | -- | -128.89% |
| SG&A Expenses | -36.52% | -33.57% | -26.29% | -16.88% | -17.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.79% | -45.29% | -40.32% | -32.30% | -25.50% |
| Operating Income | 40.79% | 44.99% | 39.27% | 30.02% | 21.71% |
| Income Before Tax | 30.90% | 34.89% | 26.35% | 18.24% | 11.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.90% | 34.89% | 26.35% | 18.24% | 11.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.90% | 34.89% | 26.35% | 18.24% | 11.19% |
| EBIT | 40.79% | 44.99% | 39.27% | 30.02% | 21.71% |
| EBITDA | 40.84% | 45.04% | 39.15% | 29.72% | 21.24% |
| EPS Basic | 34.78% | 40.00% | 29.17% | 23.08% | 14.81% |
| Normalized Basic EPS | 26.67% | 26.67% | 25.00% | 12.50% | 11.76% |
| EPS Diluted | 34.78% | 40.00% | 29.17% | 23.08% | 14.81% |
| Normalized Diluted EPS | 26.67% | 26.67% | 25.00% | 12.50% | 11.76% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |